Inhibitors for Protein alpha-N-terminal Methyltransferases
- Summary
- Researchers at Purdue University have developed new potent inhibitors for the protein NTMT. The inhibitor exhibited high selectivity to NTMT1/2 over a panel of 41 methyltransferases. These chemical compounds are novel because they are amenable for cell-based studies. They may be further optimized for animal studies. This technology is more stable and cell-permeable than existing solutions. This technology could open the door for elucidate the pharmacological functions of protein NTMT1.
- Technology Benefits
- Amenable for cell based studiesDisplays selective inhibition for NTMT1May be used for animal studies
- Technology Application
- Cell based studiesAnimal studies
- Detailed Technology Description
- Rong HuangHuang Research Lab
- Countries
- United States
- Application No.
- None
- *Abstract
-
None
- *Background
- Protein N-terminal methyltransferase 1 (NTMT1) plays an important role in regulating cell mitosis, chromatin interactions, and DNA repair. NTMT1 is over-expressed in cancer patient tissues including the head and neck, colorectal, malignant melanoma, compared to normal tissue. Knockdown of NTMT1 promotes hypersensitivity of breast cancer cell lines to double-strand DNA breaks (DSBs) by etoposide and gamma irradiation. This knowledge has made NTMT1 an important anticancer target. Currently, there are no specific cell-potent probes available for NTMT1. There is a need for a new technology that can target the NTMT1 protein.
- *IP Issue Date
- None
- *IP Type
- Provisional
- *Stage of Development
- Concept validated through theory, simulation, or models
- *Web Links
- Purdue Office of Technology CommercializationPurdue Innovation and EntrepreneurshipRong HuangHuang Research Lab
- Country/Region
- USA
For more information, please click Here
